News and Conferences

Page 4 of 16

  1. Psychedelic Therapeutics and Drug Discovery Conference

    Kendall Walker, Director of Business Development, and John Huxter, Global Head of EEG and Data Science, will attend the Psychedelic Therapeutics and Drug Discovery Conference in New Orleans, LA, USA betwen February 26-27.

  2. HW Alzheimer's and Parkinson's Drug Development Summit

    Kendall Walker, Director of Business Development, will attend the Hanson and Wade Alzheimer's and Parkinson's Drug Development Summit in Boston, MA, USA between February 3-5, 2026.

  3. HW Non-Opioid Pain Therapeutics

    Yassine Darkaby, our Pain subject matter expert on our business development team, will attend the Hanson and Wade Non-Opioid Pain Therapeutics in Boston, MA, USA between January 27-29 2026.

  4. VMX Veterinary Meeting and Expo

    Joseph Araujo, Chief Corporate Development Officer and Co-Founder, will attend the VMX Veterinary Meeting and Expo in Orlando, FL, USA between January 17-21, 2026.

  5. Biotech Showcase

    Kendall Walker, Director of Business Development, will attend the Biotech Showcase in San Francisco, CA, USA between January 12-14, 2026.

  6. Society for Neuroscience 2025, November 15-19, San Diego

    Upcoming Trip to California for the Society for Neuroscience (SfN) 2025 Meeting and Special Press Recognition for our Posters

  7. Transpharmation Enhances Global Talent Acquisition with Cykel AI Partnership

    Transpharmation has partnered with Cykel AI to enhance its recruitment capabilities using Lucy, Cykel’s autonomous AI recruitment agent. Deployed across Transpharmation’s European and North American operations, Lucy will streamline talent acquisition as the company scales its scientific teams. This enterprise-level agreement reflects Transpharmation’s commitment to innovation—not only in research, but in building world-class teams efficiently and strategically.

  8. Transpharmation Ltd. Announces Strategic Acquisition of Saretius Ltd.

    Transpharmation is pleased to announce its acquisition of Saretius Ltd. (Saretius), a pioneering British company specializing in disease models and advanced biomarker development.

  9. Society for Neuroscience 2024

    We will be attending and exhibiting at SfN 2024 in Chicago, our biggest conference of the year. Excitingly, we will be presenting FIVE posters! Make sure you visit us at Booth #872 to speak to our scientists who are attending. We look forward to seeing you there! Click to see more information on the posters being presented...

  10. Neuropsychiatric Drug Development Summit

    24th-26th September 2024. Our BD team ventured out to the Neuropsychiatric Drug Development Summit held in Boston to meet with old and new faces in the industry!

Page 4 of 16

Want to see our latest study results?

Sign up for our newsletter.

Emails with our latest study results and news, from time to time. Unsubscribe anytime. See our Privacy Policy.

Newsletters

  • What's Next in CNS Drug Discovery? Five Studies Worth Exploring
  • Advancing Science Through In Vivo Refinement and Innovation - Examples from Abuse Liability and Impulsivity Screening
  • Building Confidence in Decision Making
  • Welcome to Reading, UK
  • The Next Leap in Translational Neuroscience
  • Expanding Scientific Possibility
  • 2025 Was A Year of Momentum: Science, People and Partners
  • 2025 Was A Year of Momentum: Science, People and Partners
  • Seven Posters, One Goal: Driving Neuroscience Forward
  • Advancing Preclinical Science for Next-Gen Therapies
  • New Capabilities Coming Online
  • Discover What's New at Transpharmation
  • Unlock the Microbiome: Transform Health with Transpharmation's Advanced Studies
  • Experimental Autoimmune Encephalomyelitis (EAE): Maximising The Therapeutic Efficacy of Fingolimod
  • Cross-Species Epilepsy Research: Revealing the Potential of the Zebrafish Model
  • Monoamine depletion to induce chronic allodynia and behavioural changes: a model of fibromyalgia
  • Take your R&D pipeline into the AI era with Moseq (Motion Sequencing), our new behavioural machine-learning assay!
  • Canine Microbiome
  • Oral Health: Not just for Humans
  • Novel Object Recognition: A Reliable Assay for Addressing Cognitive Impairments in Schizophrenia
  • Pre-pulse Inhibition: A Promising Screening Tool for Novel Compounds
  • Natural and induced models of osteoarthritis in Beagle dogs
  • Utilizing Rapid Screening Tests to Assess the Antidepressant Potential of Psychedelic Analogues
  • Long-term antidepressant effect of ketamine and psilocybin in the Chronic Social Defeat stress model
  • Diabetes and Metabolic Syndrome
  • Transpharmation's Animal Health Services
  • Longevity Research Goes to the Dogs
  • Transpharmation's Cutting-Edge Antiepileptic Drug Screening: A Global Solution for Advancing Epilepsy Research
  • PTZ-treated Zebrafish provide a high throughput platform for screening novel anti-epileptic drugs
  • Beyond Seizures: Epilepsy Comorbidities Explored in Mouse Kindling Studies
  • Novelty-suppressed feeding and novelty-induced hypophagia: exploring sex differences and response to diazepam in C57BL/6J mice.
  • Development & validation of intrathecal dosing in rats and mice
  • Transpharmation's Mouse-EEG capability reveals cross-species effects of novel antidepressants ketamine and psilocybin
  • Oral Health: Not just for Humans...
  • Accelerate Your Diabetes Drug Development with Transpharmation's Dog Diabetes Models
  • Introducing our new data analysis service for tremor-plate signals!
  • Introducing the Scn1a mutant mouse model of Dravet Syndrome at Transpharmation
  • New validated pre-clinical model to assess treatments for post-surgical pain
  • Experimental Autoimmune Encephalomyelitis; Modelling Multiple Sclerosis and Beyond
  • New Preclinical Models of Migraine for Assessment of Rescue and Preventive Analgesic Treatments
  • Do Your Compounds Exhibit Anti-Inflammatory Compounds
  • Profile your anti-inflammatory compounds in primary human immune cells
  • New EEG services from Transpharmation. Read on for results...
  • Accelerate your Drug Discovery Research. Proven results, fast and cost effective
  • Urgent Treatments Needed for Parkinson's Disease
  • Poor bioavailability, is the liver or intestine to blame?
  • Laser Doppler; new validated protocols revealed.
  • Epilepsy models leading the way. Read on for results.
  • Profiling anti-inflammatory drugs; from rodent to human
  • The Mismatch Negativity Challenge
  • Accelerate your drug discovery research. Proven science based results cost-effectively.
  • Anxiety. Three preclinical tests; data revealed...
  • Seven new posters, presented at SfN, now available to view.
  • Name change announcement! News from the CEO.
  • Chronic fatigue: different etiologies influence translational models
  • Seven new translational studies to share with you at this year's SfN event. Read on for poster titles and contact details.
  • Translational value increased with non-evoked pain measures.
  • Rapid access to PK non-rodent studies. Leading expertise.
  • Essential tremor research
  • Can a psychedelic experience be modelled in rats?
  • Gender Differences in Pain. New research revealed!
  • New data on the effect of single dose psilocybin!
  • From ketamine to psychedelics, join our webinar starting tomorrow!
  • Long term delayed effects of psychedelics in preclinical models. Trailblazing results revealed!
  • Accreditation awarded with flying colours
  • Breaking news! Merger announcement between Transpharmation and InterVivo Solutions.
  • Take a look! New posters, nine therapeutic areas available to view now.
  • Nine new compelling studies to be revealed at SfN21!
  • Can changes in EEG improve neuropathic pain treatments?
  • 40Hz ASSR: sounds that change our thoughts about schizophrenia
  • Clerkenwell Health and Transpharmation combine lab and human trials for psilocybin
  • Translational endpoints for preclinical pain - improving your chances.
  • Transpharmation aims for global standard. Let's talk about lab sustainability.
  • Targeting the unmet medical need in Parkinson's Disease - the fastest growing neurological disorder.
  • Psilocybin: the power of mental reorganisation
  • Expansion to world class premises
  • Multiple therapeutic indications
  • Focus on pain
  • Gene therapies for body and brain in Duchenne Muscular Dystrophy, progress moves forward.
  • Announcing Transpharmation Poland!